

Comments on this application must be received by April 12, 1999.

Under the Federal Reserve Bank of Chicago heading, the entry for Foresight Financial Group, Inc., Freeport, Illinois, is revised to read as follows:

B. Federal Reserve Bank of Chicago (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. *Foresight Financial Group, Inc.*, Freeport, Illinois; to acquire 100 percent of the voting shares of State Bank FFG, Freeport, Illinois.

Comments on this application must be received by April 12, 1999.

Under the Federal Reserve Bank of Dallas heading, the entry for Violeta Investments, Ltd., Hebbbronville, Texas, is revised to read as follows:

C. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Violeta Investments, Ltd.*, Hebbbronville, Texas; to acquire 12.34 percent of the voting shares of Hebbbronville State Bank, Hebbbronville, Texas.

Comments on this application must be received by April 12, 1999.

Board of Governors of the Federal Reserve System, March 22, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99-7354 Filed 3-24-99; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may

express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 7, 1999.

A. Federal Reserve Bank of Chicago (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. *Northwest Financial Corporation*, Spencer, Iowa; to engage *de novo* through its subsidiary, Northwest Federal Savings Bank, Spencer, Iowa, in acquiring Gateway Savings Bank, Ankeny, Iowa (in organization), and thereby engage in the operation of a savings association, pursuant to § 225.28(b)(4)(ii) of Regulation Y.

Board of Governors of the Federal Reserve System, March 19, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99-7229 Filed 3-24-99; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING:

Committee on Employee Benefits of the Federal Reserve Systems.*

TIME AND DATE: 2:30 p.m., Tuesday, March 30, 1999.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW, Washington, DC 20551,

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Further consideration of a proposal relating to Federal Reserve System benefits.

2. Any items carried forward from a previously announced meeting.

*The Committee on Employee Benefits considers matters relating to the Retirement, Thrift, Long-Term Disability Income, and Insurance Plans for employees of the Federal Reserve System.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202-452-3204.

SUPPLEMENTARY INFORMATION: You may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement of this meeting. (The Web site also includes procedural and other information about the meeting.)

Dated: March 22, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99-7378 Filed 3-22-99; 5:00 pm]

BILLING CODE 6210-01-P

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 64 FR 13427, March 18, 1999.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 11:00 a.m., Tuesday, March 23, 1999.

CHANGES IN THE MEETING: THE OPEN MEETING HAS BEEN CANCELED, AND THE SCHEDULED ITEM WAS HANDLED VIA NOTATION VOTING.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202-452-3204.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 for a recorded announcement of this meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement. (The Web site also includes procedural and other information about the open meeting.)

Dated: March 23, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99-7412 Filed 3-23-99; 12:28 pm]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Ms. Maria Diaz, Rush-Presbyterian-St. Luke's Medical Center: Based on the report of the Rush-Presbyterian-St. Luke's Medical Center (RPMC) Research Integrity Investigation Committee dated May 13, 1998, which included a report of a special National Cancer Institute (NCI) audit, and additional information obtained by ORI during its oversight review, ORI finds that Ms. Diaz, former data manager for two multicenter cancer prevention clinical trials at RPMC,

engaged in scientific misconduct in this clinical research supported by NCI, National Institutes of Health (NIH), cooperative agreements.

Specifically, Ms. Diaz intentionally fabricated and/or falsified research data and information collected at RPMC for the Breast Cancer Prevention Trial (BCPT) under the National Surgical Adjuvant Breast and Bowel Project (NSABP) and a secondary prevention trial for lung cancer sponsored by the M.D. Anderson Cancer Center and Eastern Cooperative Oncology Group (ECOG). Ms. Diaz falsified data related to entry criteria and treatment compliance on the secondary lung cancer prevention trial. She fabricated reports of follow-up examinations for subjects entered on the BCPT, falsified laboratory test results, and forged signatures of physicians on informed consent documents.

ORI has implemented the following administrative actions for the three (3) year period beginning March 13, 1999:

(1) Ms. Diaz is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) Any institution that submits an application for PHS support for a research project on which Ms. Diaz's participation is proposed or which uses her in any capacity on PHS supported research, or that submits a report of PHS-funded research in which she is involved, must concurrently submit a plan for supervision of her duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Ms. Diaz's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations Office of Research Integrity 5515 Security Lane, Suite 700 Rockville, MD 20852 (301) 443-5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.
[FR Doc. 99-7234 Filed 3-24-99 8:45 am]

BILLING CODE 4160-17-U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98P-0043]

Agency Information Collection Activities; Announcement of OMB Approval; Food Labeling: Nutrition Labeling of Dietary Supplements on a "Per Day" Basis

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Food Labeling: Nutrition Labeling of Dietary Supplements on a "Per Day" Basis" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of January 12, 1999 (64 FR 1765), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-395. The approval expires on March 31, 2002. A copy of the supporting statement for this information collection is available on the Internet at "http://www.fda.gov/ohrms/dockets".

Dated: March 17, 1999.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 99-7233 Filed 3-24-99; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99F-0487]

Exxon Chemical Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Exxon Chemical Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of fatty acids, C10-13-branched, vinyl esters as a comonomer in polymers used as components of adhesive formulations intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS-215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3081.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 9B4650) has been filed by Exxon Chemical Co., P.O. Box 3272, Houston, TX 77253-3272. The petition proposes to amend the food additive regulations in § 175.105 Adhesives (21 CFR 175.105) to provide for the safe use of fatty acids, C 10-13-branched, vinyl esters as a comonomer in polymers used as components of adhesive formulations intended for use in contact with food.

The agency has determined under 21 CFR 25.32(i) that this action is of the type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: March 5, 1999.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 99-7231 Filed 3-24-99; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 77N-0240; DESI 1786]

Nitroglycerin Transdermal System; Opportunity for a Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is proposing to withdraw approval of one new drug application (NDA) and five abbreviated new drug applications (ANDA's) for certain single-entity coronary vasodilator drug products containing nitroglycerin in a transdermal system.